Overview

A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)

Status:
Completed
Trial end date:
2018-11-07
Target enrollment:
Participant gender:
Summary
This study will evaluate weight gain of ALKS 3831 compared to olanzapine in adult subjects with schizophrenia.
Phase:
Phase 3
Details
Lead Sponsor:
Alkermes, Inc.
Treatments:
Olanzapine